|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
|
EP1572902B1
(en)
|
2002-02-01 |
2014-06-11 |
Life Technologies Corporation |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
|
WO2003064625A2
(en)
|
2002-02-01 |
2003-08-07 |
Sequitur, Inc. |
Oligonucleotide compositions with enhanced efficiency
|
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
ATE485394T1
(de)
|
2003-06-02 |
2010-11-15 |
Univ Massachusetts |
Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
|
|
US7459547B2
(en)
*
|
2003-06-02 |
2008-12-02 |
University Of Massachusetts |
Methods and compositions for controlling efficacy of RNA silencing
|
|
ES2485848T3
(es)
*
|
2003-09-12 |
2014-08-14 |
University Of Massachusetts |
ARN de interferencia para el tratamiento de trastornos relacionados con la ganancia de función
|
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
|
US20070265220A1
(en)
*
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
US8084599B2
(en)
|
2004-03-15 |
2011-12-27 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
WO2006085987A2
(en)
|
2004-07-09 |
2006-08-17 |
University Of Iowa Research Foundation |
Rna interference in respiratory epitheial cells
|
|
US20060142228A1
(en)
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
|
GB2421948A
(en)
*
|
2004-12-30 |
2006-07-12 |
Ist Superiore Sanita |
Retrotransposon inhibition to treat cancer
|
|
US20070213293A1
(en)
*
|
2005-04-08 |
2007-09-13 |
Nastech Pharmaceutical Company Inc. |
Rnai therapeutic for respiratory virus infection
|
|
US8252756B2
(en)
|
2005-06-14 |
2012-08-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
|
WO2007022470A2
(en)
*
|
2005-08-18 |
2007-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating neurological disease
|
|
US20080124365A1
(en)
*
|
2006-05-24 |
2008-05-29 |
Genolution Pharmaceuticals, Inc. |
Innate immune response inducer
|
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
US9506056B2
(en)
|
2006-06-08 |
2016-11-29 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
|
EP4082551A1
(en)
|
2006-08-08 |
2022-11-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Structure and use of 5' phosphate oligonucleotides
|
|
EP2076600A1
(en)
*
|
2006-10-18 |
2009-07-08 |
Nastech Pharmaceutical Company Inc. |
Nicked or gapped nucleic acid molecules and uses thereof
|
|
CA2691066C
(en)
|
2007-02-09 |
2018-07-31 |
Northwestern University |
Particles for detecting intracellular targets
|
|
JP5311854B2
(ja)
|
2007-03-23 |
2013-10-09 |
キヤノン株式会社 |
電子写真画像形成装置、現像装置、及び、カップリング部材
|
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
|
AU2013273719B2
(en)
*
|
2007-05-22 |
2016-04-14 |
Arcturus Therapeutics, Inc. |
UNA amidites for therapeutic oligomers
|
|
US8314227B2
(en)
|
2007-05-22 |
2012-11-20 |
Marina Biotech, Inc. |
Hydroxymethyl substituted RNA oligonucleotides and RNA complexes
|
|
UY31267A1
(es)
|
2007-08-03 |
2009-01-05 |
Alcon Res Ltd |
Inhibición del pasaje de senalización del tnfa relacionada con arni para el tratamiento de la angiogénesis ocular
|
|
DK2193140T3
(en)
*
|
2007-08-27 |
2017-01-23 |
Iglobe Health Inst Llc |
COMPOSITIONS OF ASYMMETRIC INTERFERRING RNA AND ITS APPLICATIONS
|
|
EP2548962B1
(en)
|
2007-09-19 |
2016-01-13 |
Applied Biosystems, LLC |
Sirna sequence-independent modification formats for reducing off-target phenotypic effects in rnai, and stabilized forms thereof
|
|
TW200927177A
(en)
*
|
2007-10-24 |
2009-07-01 |
Nat Inst Of Advanced Ind Scien |
Lipid-modified double-stranded RNA having potent RNA interference effect
|
|
US8030290B2
(en)
*
|
2007-12-07 |
2011-10-04 |
City Of Hope |
Cell-type specific aptamer-siRNA delivery system for HIV-1 Therapy
|
|
EP2297323A1
(en)
|
2008-05-21 |
2011-03-23 |
Hartmann, Gunther |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
US20110136233A1
(en)
*
|
2008-08-05 |
2011-06-09 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting plk1 gene expression and uses thereof
|
|
EP2323695B1
(en)
|
2008-08-19 |
2018-12-05 |
Nektar Therapeutics |
Complexes of small-interfering nucleic acids
|
|
DK2341943T3
(en)
*
|
2008-09-22 |
2019-02-25 |
Dicerna Pharmaceuticals Inc |
COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS
|
|
CN102281872A
(zh)
|
2008-11-24 |
2011-12-14 |
西北大学 |
多价rna纳米颗粒组合物
|
|
BRPI0922355A8
(pt)
|
2008-12-03 |
2017-12-12 |
Marina Biotech Inc |
Ácidos nucléicos, métodos para reduzir a expressão de um gene em uma célula in vitro, uso do ácido nucléico, complexo de rna e uso do complexo de rna
|
|
US20100249214A1
(en)
|
2009-02-11 |
2010-09-30 |
Dicerna Pharmaceuticals |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
CN102325534B
(zh)
|
2008-12-18 |
2016-02-17 |
戴瑟纳制药公司 |
延长的dicer酶底物和特异性抑制基因表达的方法
|
|
US11408003B2
(en)
|
2008-12-18 |
2022-08-09 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
|
CN102575254B
(zh)
|
2009-04-03 |
2015-03-04 |
戴瑟纳制药公司 |
利用不对称双链rna特异性抑制kras的方法和组合物
|
|
EP2756845B1
(en)
|
2009-04-03 |
2017-03-15 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
|
|
WO2010141724A2
(en)
*
|
2009-06-03 |
2010-12-09 |
Dicerna Pharmaceuticals, Inc. |
Peptide dicer substrate agents and methods for their specific inhibition of gene expression
|
|
WO2010141933A1
(en)
*
|
2009-06-05 |
2010-12-09 |
Dicerna Pharmaceuticals, Inc. |
Specific inhibition of gene expression by nucleic acid containing a dicer substrate
|
|
AU2010259295B2
(en)
|
2009-06-10 |
2015-05-07 |
Temasek Life Sciences Laboratory Limited |
Virus induced gene silencing (VIGS) for functional analysis of genes in cotton.
|
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
WO2011032100A1
(en)
|
2009-09-11 |
2011-03-17 |
Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Inhibitors of kshv vil6 and human il6
|
|
WO2011035065A1
(en)
|
2009-09-17 |
2011-03-24 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
|
CA2775092A1
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
KR20120136345A
(ko)
|
2009-10-30 |
2012-12-18 |
노오쓰웨스턴 유니버시티 |
주형화된 나노컨쥬게이트
|
|
WO2011072082A2
(en)
|
2009-12-09 |
2011-06-16 |
Nitto Denko Corporation |
Modulation of hsp47 expression
|
|
JP5257796B2
(ja)
*
|
2009-12-28 |
2013-08-07 |
株式会社村田製作所 |
固体電解コンデンサ素子及びその製造方法
|
|
WO2011109294A1
(en)
*
|
2010-03-01 |
2011-09-09 |
Dicerna Pharmaceuticals, Inc. |
Lipid delivery formulations
|
|
JP5767207B2
(ja)
|
2010-03-26 |
2015-08-19 |
協和発酵キリン株式会社 |
新規修飾部位導入抗体および抗体フラグメント
|
|
WO2011133878A2
(en)
*
|
2010-04-22 |
2011-10-27 |
University Of Utah Research Foundation |
Compositions and methods for selectively producing sirna
|
|
US9408914B2
(en)
|
2010-04-28 |
2016-08-09 |
Kyowa Hakko Kirin Co., Ltd. |
Cationic lipid
|
|
WO2011136369A1
(ja)
|
2010-04-28 |
2011-11-03 |
協和発酵キリン株式会社 |
カチオン性脂質
|
|
DK3587579T3
(da)
|
2010-07-06 |
2021-04-26 |
Dicerna Pharmaceuticals Inc |
Fremgangsmåder og sammensætninger til specifik hæmning af beta-catenin ved hjælp af dobbeltstrenget rna
|
|
WO2012006241A2
(en)
*
|
2010-07-06 |
2012-01-12 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
|
|
WO2012051491A1
(en)
|
2010-10-14 |
2012-04-19 |
The United States Of America, As Represented By The Secretary National Institutes Of Health |
Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
|
|
CN103492572A
(zh)
|
2011-03-03 |
2014-01-01 |
夸克医药公司 |
用于治疗肺疾病和损伤的组合物和方法
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
|
TWI658830B
(zh)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Ｈｓｐ47表現調控強化用類視色素脂質體
|
|
SG10201604726YA
(en)
|
2011-06-10 |
2016-07-28 |
Temasek Life Sciences Lab Ltd |
Genetic manipulation and expression systems for pucciniomycotina and ustilaginomycotina subphyla
|
|
ES2856091T3
(es)
|
2011-09-14 |
2021-09-27 |
Univ Northwestern |
Nanoconjugados capaces de atravesar la barrera hematoencefálica
|
|
ES2897565T3
(es)
|
2011-10-18 |
2022-03-01 |
Dicerna Pharmaceuticals Inc |
Lípidos catiónicos de amina y uso de los mismos
|
|
EP2757961A2
(en)
*
|
2011-10-27 |
2014-07-30 |
Occlutech Holding AG |
A medical implant for occluding an opening in a body and a method of producing such a medical implant.
|
|
JP2013095755A
(ja)
|
2011-11-02 |
2013-05-20 |
Kyowa Hakko Kirin Co Ltd |
カチオン性脂質
|
|
EP2792368A4
(en)
|
2011-12-12 |
2015-09-30 |
Kyowa Hakko Kirin Co Ltd |
LIPID NANOPARTICLES WITH COMBINATIONS OF CATIONIC LIPIDES
|
|
EP2792367A4
(en)
|
2011-12-12 |
2015-09-30 |
Kyowa Hakko Kirin Co Ltd |
LIPID NANOPARTICLES FOR A DRUG DELIVERY SYSTEM CONTAINING CATIONIC LIPIDS
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
NZ700075A
(en)
|
2012-02-24 |
2016-05-27 |
Protiva Biotherapeutics Inc |
Trialkyl cationic lipids and methods of use thereof
|
|
US10100321B2
(en)
|
2012-04-19 |
2018-10-16 |
Temasek Life Sciences Laboratory Limited |
Methods for increasing cotton fiber length
|
|
US9272016B2
(en)
|
2012-04-20 |
2016-03-01 |
University Of Iowa Research Foundation |
Methods to enhance RNAi oligonucleotide delivery to respiratory epithelial cells
|
|
TW201726599A
(zh)
|
2012-07-06 |
2017-08-01 |
協和醱酵麒麟有限公司 |
陽離子性脂質
|
|
JP6106671B2
(ja)
*
|
2012-07-17 |
2017-04-05 |
株式会社ステリック再生医科学研究所 |
粘膜治癒促進剤
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
WO2014034934A1
(ja)
|
2012-08-31 |
2014-03-06 |
協和発酵キリン株式会社 |
オリゴヌクレオチド
|
|
RU2657749C2
(ru)
|
2012-09-21 |
2018-06-15 |
Интенсити Терапьютикс, Инк |
Способы лечения рака
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
WO2014055825A1
(en)
|
2012-10-04 |
2014-04-10 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
A formulation of mycobacterial components as an adjuvant for inducing th17 responses
|
|
CN105189541A
(zh)
|
2012-12-14 |
2015-12-23 |
戴瑟纳制药公司 |
用于通过双链rna特异性抑制ckap5的方法和组合物
|
|
US10258682B2
(en)
|
2013-01-16 |
2019-04-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Attenuated chlamydia vaccine
|
|
SG10201706960TA
(en)
|
2013-02-28 |
2017-10-30 |
Arrowhead Res Corp |
Organic compositions to treat epas1-related diseases
|
|
KR102205278B1
(ko)
|
2013-03-14 |
2021-01-22 |
다이서나 파마수이티컬, 인크. |
음이온성 약제를 제형화하는 방법
|
|
US9546364B2
(en)
|
2013-03-15 |
2017-01-17 |
Carnegie Mellon University |
Synthetic lariat RNA for RNA interference
|
|
PL3444350T3
(pl)
|
2013-07-03 |
2022-03-21 |
Dicerna Pharmaceuticals, Inc. |
Sposoby i kompozycje do specyficznego hamowania alfa-1 antytrypsyny przez dwuniciowy rna
|
|
JP6064251B2
(ja)
*
|
2013-07-19 |
2017-01-25 |
ホアウェイ・テクノロジーズ・カンパニー・リミテッド |
動的適応型ハイパーテキスト転送プロトコルストリーミングにおけるメタデータ情報のシグナリングおよび搬送
|
|
SG11201600379TA
(en)
|
2013-08-07 |
2016-02-26 |
Arrowhead Res Corp |
Polyconjugates for delivery of rnai triggers to tumor cells in vivo
|
|
AU2014360314B2
(en)
|
2013-12-06 |
2018-04-26 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
|
|
RS61892B1
(sr)
|
2013-12-27 |
2021-06-30 |
Dicerna Pharmaceuticals Inc |
Postupci i kompozicije za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
|
|
JPWO2015108162A1
(ja)
|
2014-01-17 |
2017-03-23 |
協和発酵キリン株式会社 |
β２ＧＰＩの発現を抑制する核酸
|
|
CA2946719C
(en)
|
2014-03-25 |
2023-09-26 |
Arcturus Therapeutics, Inc. |
Una oligomers having reduced off-target effects in gene silencing
|
|
JP6771387B2
(ja)
|
2014-03-25 |
2020-10-21 |
アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー
|
|
US9856475B2
(en)
|
2014-03-25 |
2018-01-02 |
Arcturus Therapeutics, Inc. |
Formulations for treating amyloidosis
|
|
US9987299B2
(en)
|
2014-05-05 |
2018-06-05 |
University Of Iowa Research Foundation |
Methods of improving RNAi in well-differentiated airway epithelia
|
|
WO2015171827A1
(en)
|
2014-05-06 |
2015-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Triggering rna interference with rna-dna and dna-rna nanoparticles
|
|
JP6779866B2
(ja)
|
2014-06-13 |
2020-11-04 |
チルドレンズ メディカル センター コーポレイション |
ミトコンドリアを単離するための製品および方法
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
KR101670254B1
(ko)
*
|
2014-07-09 |
2016-10-28 |
서울대학교산학협력단 |
목적 유전자의 발현 억제 특이성이 증가된 siRNA 분자
|
|
AU2015305482B2
(en)
|
2014-08-19 |
2021-04-01 |
Northwestern University |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
|
JP2016071140A
(ja)
|
2014-09-30 |
2016-05-09 |
富士フイルム株式会社 |
ズームレンズおよび撮像装置
|
|
AU2015330670B2
(en)
|
2014-10-10 |
2022-01-06 |
Novo Nordisk Health Care Ag |
Therapeutic inhibition of lactate dehydrogenase and agents therefor
|
|
TWI755351B
(zh)
*
|
2014-10-10 |
2022-02-21 |
美商艾爾妮蘭製藥公司 |
用於抑制ｈａｏ１（羥酸氧化酶１（乙醇酸鹽氧化酶））基因表現的組合物及方法
|
|
WO2016064347A1
(en)
|
2014-10-22 |
2016-04-28 |
Temasek Life Sciences Laboratory Limited |
Terpene synthases from ylang ylang (cananga odorata var. fruticosa)
|
|
US11213593B2
(en)
|
2014-11-21 |
2022-01-04 |
Northwestern University |
Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
|
|
ES2747842T3
(es)
|
2014-12-15 |
2020-03-11 |
Dicerna Pharmaceuticals Inc |
Acidos nucleicos de doble hebra modificados por ligando
|
|
US10264976B2
(en)
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
|
US10036017B2
(en)
|
2015-02-17 |
2018-07-31 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
|
|
JP6773677B2
(ja)
|
2015-03-17 |
2020-10-21 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
改善されたジスルフィド含有アルキン連結剤
|
|
WO2016149331A2
(en)
|
2015-03-17 |
2016-09-22 |
Arrowhead Research Corporation |
Compositions and methods for inhibiting gene expression of factor xii
|
|
US10519447B2
(en)
|
2015-04-01 |
2019-12-31 |
Arcturus Therapeutics, Inc. |
Therapeutic UNA oligomers and uses thereof
|
|
WO2016183009A2
(en)
|
2015-05-08 |
2016-11-17 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of antithrombin 3 (at3) by double-stranded rna
|
|
AU2016270597B2
(en)
|
2015-05-29 |
2022-05-26 |
Arrowhead Pharmaceuticals, Inc. |
Biologically cleavable tetrapeptide linking agents
|
|
WO2016196239A1
(en)
|
2015-05-29 |
2016-12-08 |
Arrowhead Pharmaceuticals, Inc. |
Compositions and methods for inhibiting gene expression of hif2alpha
|
|
WO2017015671A1
(en)
|
2015-07-23 |
2017-01-26 |
Arcturus Therapeutics, Inc. |
Compositions for treating amyloidosis
|
|
WO2017027350A2
(en)
|
2015-08-07 |
2017-02-16 |
Arrowhead Pharmaceuticals, Inc. |
Rnai therapy for hepatitis b virus infection
|
|
JOP20210043A1
(ar)
|
2015-10-01 |
2017-06-16 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
|
WO2017095946A1
(en)
|
2015-11-30 |
2017-06-08 |
Flagship Pioneering, Inc. |
Methods and compositions relating to chondrisomes
|
|
CN108367022A
(zh)
|
2015-12-13 |
2018-08-03 |
日东电工株式会社 |
具有高活性和降低脱靶的sirna结构
|
|
EP3395797B1
(en)
|
2015-12-25 |
2025-08-06 |
Kyowa Kirin Co., Ltd. |
Compounds as cationic lipids
|
|
CN105462932A
(zh)
*
|
2015-12-29 |
2016-04-06 |
同济大学苏州研究院 |
一种采用慢病毒技术构建的抗肿瘤迁移药物筛选细胞模型及其应用方法
|
|
FI4272834T3
(fi)
|
2016-01-15 |
2025-12-05 |
Childrens Medical Ct Corp |
Mitokondrioiden ja yhdistettyjen mitokondriaalisten aineiden terapeuttinen käyttö
|
|
US12447166B2
(en)
|
2016-02-25 |
2025-10-21 |
Applied Biological Laboratories, Inc. |
Compositions and methods for protecting against airborne pathogens and irritants
|
|
AU2017224113B2
(en)
|
2016-02-25 |
2022-04-21 |
Applied Biological Laboratories, Inc. |
Compositions and methods for protecting against airborne pathogens and irritants
|
|
MA45470A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques kras et leurs utilisations
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
EP3436582B1
(en)
|
2016-04-01 |
2021-10-13 |
Avidity Biosciences, Inc. |
Beta-catenin nucleic acids and uses thereof
|
|
WO2017173301A1
(en)
|
2016-04-01 |
2017-10-05 |
Avidity Biosciences Llc |
Egfr nucleic acids and uses thereof
|
|
CN107333099B
(zh)
*
|
2016-04-28 |
2019-11-19 |
瑞昱半导体股份有限公司 |
具有无线中继功能的网络摄影机
|
|
WO2018013509A1
(en)
|
2016-07-11 |
2018-01-18 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for diagnosing and treating arrhythmias
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
MX2019008252A
(es)
|
2017-01-10 |
2019-09-06 |
Arrowhead Pharmaceuticals Inc |
Agentes de interferencia de acido ribonucleico (iarn) de alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y metodos de uso.
|
|
WO2018140630A1
(en)
|
2017-01-25 |
2018-08-02 |
Northwestern University |
Autophagy inducers for treatment of cns conditions
|
|
WO2018164186A1
(ja)
|
2017-03-09 |
2018-09-13 |
協和発酵キリン株式会社 |
Ｍａｓｐ２の発現を抑制する核酸
|
|
WO2018187373A1
(en)
|
2017-04-03 |
2018-10-11 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Functionally-interdependent shape switching nucleic acid nanoparticles
|
|
KR102677783B1
(ko)
*
|
2017-04-28 |
2024-06-21 |
쿄와 기린 가부시키가이샤 |
올리고뉴클레오티드 유도체 또는 그 염
|
|
US11433131B2
(en)
|
2017-05-11 |
2022-09-06 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (SNAs)
|
|
KR20200014320A
(ko)
|
2017-05-31 |
2020-02-10 |
쿄와 기린 가부시키가이샤 |
Apcs의 발현을 억제하는 핵산
|
|
AU2018285860A1
(en)
|
2017-06-13 |
2020-01-02 |
Flagship Pioneering Innovations V, Inc. |
Compositions comprising curons and uses thereof
|
|
AU2018301829B2
(en)
|
2017-07-13 |
2024-08-01 |
Alnylam Pharmaceuticals, Inc. |
Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase) gene expression
|
|
CA3071968A1
(en)
|
2017-08-04 |
2019-02-07 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticle
|
|
CN111448319B
(zh)
|
2017-10-13 |
2024-05-17 |
诺和诺德保健股份有限公司 |
用于抑制ldha表达的方法和组合物
|
|
US10815484B2
(en)
|
2017-11-22 |
2020-10-27 |
The Regents Of The University Of Michigan |
Compositions and methods for treating cancer
|
|
CN118638787A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
BR112020011670A2
(pt)
|
2017-12-15 |
2020-11-17 |
Flagship Pioneering Innovations Vi, Llc. |
composições compreendendo polirribonucleotídeos circulares e seus usos
|
|
US11746151B2
(en)
|
2018-04-13 |
2023-09-05 |
The Regents Of The University Of Michigan |
Compositions and methods for treating cancer
|
|
EP4365289A3
(en)
|
2018-11-16 |
2024-07-10 |
Nitto Denko Corporation |
Rna interference delivery formulation and methods for malignant tumors
|
|
AU2019390097A1
(en)
|
2018-11-30 |
2021-07-15 |
Kyowa Kirin Co., Ltd. |
Nucleic acid conjugate
|
|
CA3120580A1
(en)
|
2019-01-09 |
2020-07-16 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
|
|
US12215382B2
(en)
|
2019-03-01 |
2025-02-04 |
The General Hospital Corporation |
Liver protective MARC variants and uses thereof
|
|
CA3131319A1
(en)
|
2019-03-25 |
2020-10-01 |
Avak Kahvejian |
Compositions comprising modified circular polyribonucleotides and uses thereof
|
|
US20220154189A1
(en)
|
2019-03-29 |
2022-05-19 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for the treatment of kras associated diseases or disorders
|
|
MX2022002533A
(es)
|
2019-08-30 |
2022-06-02 |
Dicerna Pharmaceuticals Inc |
Ácidos nucleicos modificados con ligandos 2', síntesis de estos y compuestos intermedios de estos.
|
|
CA3147643A1
(en)
|
2019-09-23 |
2021-04-01 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression
|
|
EP4048807A1
(en)
|
2019-09-23 |
2022-08-31 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein b (apob) gene expression
|
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
|
TW202142689A
(zh)
|
2020-01-29 |
2021-11-16 |
美商旗艦先鋒創新有限責任公司 |
用於轉譯之組合物及其使用方法
|
|
EP4118207A1
(en)
|
2020-03-11 |
2023-01-18 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
AU2021237465A1
(en)
|
2020-03-19 |
2022-10-13 |
Avidity Biosciences, Inc. |
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
|
|
EP4127134A4
(en)
|
2020-04-01 |
2024-07-31 |
Alnylam Pharmaceuticals, Inc. |
COMPOSITIONS OF ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) ARNI AGENTS AND METHODS OF USE THEREOF
|
|
EP4100028A4
(en)
|
2020-08-20 |
2023-07-26 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
WO2022040444A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
|
EP4097486A4
(en)
|
2020-08-20 |
2023-09-06 |
A2 Biotherapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF POSITIVE CANCERS AT CEACAM
|
|
WO2022125725A1
(en)
|
2020-12-09 |
2022-06-16 |
The Regents Of The University Of Michigan |
Compositions and methods for treating wnt-driven cancer
|
|
CA3206361A1
(en)
|
2020-12-23 |
2022-06-30 |
Flagship Pioneering Innovations V, Inc. |
In vitro assembly of anellovirus capsids enclosing rna
|
|
AU2022221606A1
(en)
|
2021-02-16 |
2023-08-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating her2 positive cancers
|
|
EP4321524B1
(en)
|
2021-04-09 |
2025-12-10 |
Sogo Pharmaceutical Co., Ltd. |
Lipid and composition
|
|
WO2022263931A2
(en)
|
2021-06-17 |
2022-12-22 |
Oslo Universitetssykehus Hf |
Compositions and methods for treating cancer
|
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
CN117897483A
(zh)
|
2021-08-25 |
2024-04-16 |
戴瑟纳制药公司 |
用于抑制α-1抗胰蛋白酶表达的组合物和方法
|
|
MX2024003519A
(es)
|
2021-09-24 |
2024-04-01 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
|
|
JP2024539512A
(ja)
|
2021-10-22 |
2024-10-28 |
セイル バイオメディシンズ インコーポレイテッド |
Ｍｒｎａワクチン組成物
|
|
US20230159930A1
(en)
|
2021-11-19 |
2023-05-25 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof
|
|
CN118488834A
(zh)
|
2021-11-23 |
2024-08-13 |
赛欧生物医药股份有限公司 |
细菌源性脂质组合物和其用途
|
|
EP4452239A1
(en)
|
2021-12-20 |
2024-10-30 |
Sail Biomedicines, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
|
WO2023220561A1
(en)
|
2022-05-09 |
2023-11-16 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof
|
|
CN119487196A
(zh)
|
2022-05-13 |
2025-02-18 |
旗舰创业创新七公司 |
双链dna组合物及相关方法
|
|
KR20250046303A
(ko)
|
2022-08-05 |
2025-04-02 |
사네진 바이오 유에스에이 인크. |
안지오텐시노겐 (agt)을 표적화하는 이중 가닥 rna 및 그의 사용 방법
|
|
WO2024081954A2
(en)
|
2022-10-14 |
2024-04-18 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting c3 and uses thereof
|
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
EP4638743A2
(en)
|
2022-12-19 |
2025-10-29 |
Sanegene Bio USA Inc. |
Small interfering rna targeting cfb and uses thereof
|
|
WO2024159172A1
(en)
|
2023-01-27 |
2024-08-02 |
Senda Biosciences, Inc. |
A modified lipid composition and uses thereof
|
|
IL322201A
(en)
|
2023-02-17 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
DNA structures containing modified uracil
|
|
WO2024173836A2
(en)
|
2023-02-17 |
2024-08-22 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified cytosine
|
|
WO2024175111A2
(en)
|
2023-02-24 |
2024-08-29 |
Suzhou Sanegene Bio Inc. |
Small interfering rna targeting hbv and uses thereof
|
|
WO2024186673A2
(en)
|
2023-03-03 |
2024-09-12 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting apoc3 and uses thereof
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
WO2024220625A1
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
US20250027089A1
(en)
|
2023-06-21 |
2025-01-23 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting proprotein convertase subtilisin kexin 9 (pcsk9) and methods of use thereof
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025133951A1
(en)
|
2023-12-21 |
2025-06-26 |
Genevant Sciences Gmbh |
Ionizable lipids suitable for lipid nanoparticles
|
|
WO2025228441A2
(en)
|
2024-04-30 |
2025-11-06 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting inhbe and uses thereof
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026017140A2
(en)
|
2024-07-18 |
2026-01-22 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting fxi and uses thereof
|
|
WO2026022656A2
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Lipid particle formulations with permanently charged cationic lipids
|
|
WO2026022677A1
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Permanently charged cationic lipids
|
|
WO2026041067A2
(en)
|
2024-08-20 |
2026-02-26 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting myostatin (mstn) and uses thereof
|
|
WO2026046411A1
(en)
|
2024-09-02 |
2026-03-05 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting plasminogen (plg) and uses thereof
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|